Author(s) :

Nethra Chintaboina.

Volume/Issue :

Abstract :

Diabetes mellitus remains one of the most pressing global health challenges, with existing treatments largely focused on managing symptoms rather than addressing root causes. CRISPR-Cas9 genome editing technology offers an opportunity to reshape therapeutic strategies for both Type 1 and Type 2 diabetes. In Type 1 diabetes, CRISPR has been employed to enhance the survival and function of insulin-producing cells and to reduce harmful immune responses. For Type 2 diabetes, researchers are focusing on how genetic interventions can help regulate blood sugar levels and reduce inflammation. This review highlights current clinical applications and various ethical considerations related to germline editing, equitable access, and off-target risks. Through the explanation of cutting-edge research, this review underscores CRISPR-Cas9’s role in redefining the future of diabetes therapy.